-
Study aim
-
Determining the effects of treatment with premarin and clobetasol-premarin in the vaginal involvement of graft-versus-host disease (transplant-induced GVHD)
-
Design
-
Randomized Clinical trial, with parallel groups, randomized, on 55, which is used for randomization of double blocks.
-
Settings and conduct
-
Patients referred to Shariati Hospital in Tehran who underwent bone marrow transplantation. After identifying the patients, the rate of response to steroid and premarin treatment is evaluated. Also, clinical symptoms such as vaginal dryness, burning sensation during urination, pelvic pain, vulva ulcer, vaginal discharge, vaginal inflammation, scar in the clitoris, vaginal shortening, vaginal tightness, vaginal closure (as well as complications due to transplantation, duration The occurrence of GVHD after transplantation, the prevalence of vaginal GVHD) is also recorded. The type of transplanted cells (allogeneic or autologous) is also investigated.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: patients who receive a bone marrow cell transplant; have no disease in the genital area before transplantation; have genital involvement including vaginal involvement after bone marrow transplantation; those who have informed consent to participate in the study. Exclusion criteria: patients without informed consent or death during the study.
-
Intervention groups
-
In the first group, Peremarin cream is used once a day along with the mold, and in the second group, clobetasol-peremarin combined treatment is used every other day (for 6 weeks).
-
Main outcome variables
-
Vaginal involvement of graft-versus-host disease transplant-induced GVHD